Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
Nymox Pharmaceutical Corporation (NYMXF) had Non-Operating Income/Expense of $-0.49M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-8.84M |
|
-- |
|
-- |
|
$8.35M |
|
$-8.35M |
|
|
Non-Operating Income/Expense |
$-0.49M |
$-8.84M |
|
$-8.84M |
|
$-8.84M |
|
$-8.84M |
|
$-8.84M |
|
$-8.84M |
|
$-8.35M |
|
$-8.18M |
|
91.69M |
|
91.69M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$0.62M |
|
$0.00M |
|
$0.00M |
|
$0.63M |
|
$3.80M |
|
-- |
|
-- |
|
$3.80M |
|
$-3.17M |
|
$-3.17M |
|
$-3.17M |
|
93.54M |
|
| Cash Flow Statement Financials | |
$-4.06M |
|
$-0.00M |
|
$2.73M |
|
$1.40M |
|
$0.07M |
|
$-1.33M |
|
$3.36M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.06M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
278.73% |
|
278.73% |
|
-1410.53% |
|
278.73% |
|
$-0.03 |
|
$-0.04 |
|
$-0.04 |
|